patent/BG-103155-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/BG-103155-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_56666880a5e2b7703e98a4f9b2d9daf6
classificationCPCAdditional	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01L2924-0002
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D261-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01L23-4006 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/H01L23-427
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D261-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D- http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/H01L23-427 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/H01L23-40
filingDate	1999-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b38aae1f08f88805f1f8e54fd5c751df http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_adccaeef9ba9cf22b1fea0c886a6be59 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44e077ecbff7f66f59880e613982bcc3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fa4a56ba7601faaef3c3427723febc01 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d52a2cc2ef62834eb5603844f98df35c
publicationDate	1999-11-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	BG-103155-A
titleOfInvention	Crystalline form of 4- [5-methyl-3-phenylisoxazol-4-yl] -benzenesulfonamide
abstract	The invention relates to crystalline form of 4- [5-methyl-3-phenylisoxazol-4-yl] benzenesulfonamide with increased stability, melting point from 170 to 740 < 0 > C and other physical characteristics. and 'for the treatment of cyclooxygenase-2 (COX-2) related disorders, including inflammation.
priorityDate	1996-08-14-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID119607 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410878039

Total number of triples: 33.